BiotechTube
certus molecular diagnostics

certus molecular diagnostics

Pre-clinical
Zollikofen, SwitzerlandFounded 2017certusdiagnostics.com

Certus Molecular Diagnostics AG is a privately held Swiss company established in 2017 by a physician and a biologist to solve critical diagnostic challenges in biotechnology and research laboratories. The company's core mission is to set new standards in diagnostics by combining clinical and diagnostic expertise to create rapid, simple, and reliable molecular tests. It has won several entrepreneurial awards and launched multiple products internationally, supported by a consortium of Swiss innovation grants and foundations. Certus is positioned to capture market share by replacing time-consuming, laborious, and unreliable current procedures for pathogen detection.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $15.2M

AI Company Overview

Certus Molecular Diagnostics AG is a privately held Swiss company established in 2017 by a physician and a biologist to solve critical diagnostic challenges in biotechnology and research laboratories. The company's core mission is to set new standards in diagnostics by combining clinical and diagnostic expertise to create rapid, simple, and reliable molecular tests. It has won several entrepreneurial awards and launched multiple products internationally, supported by a consortium of Swiss innovation grants and foundations. Certus is positioned to capture market share by replacing time-consuming, laborious, and unreliable current procedures for pathogen detection.

Infectious DiseaseBiotechnology Quality Control

Technology Platform

A proprietary molecular diagnostics platform enabling laboratory-quality, on-site detection of pathogens with a 30-minute time-to-result and only 5 minutes of hands-on time.

Funding History

2
Total raised:$15.2M
Series A$12MNov 15, 2022
Seed$3.2MMar 15, 2020

Opportunities

The primary opportunity is displacing slow, send-out PCR and unreliable rapid tests in the global biotech/R&D quality control market.
The platform can be expanded to detect other critical contaminants (e.g., viruses, bacteria) in bioprocessing, and potentially into adjacent markets like veterinary diagnostics, food safety, or human point-of-care testing.

Risk Factors

Key risks include the need for broad validation of its performance claims against established methods, slow adoption in a conservative industry, limited current product scope, and potential competition from larger, well-funded diagnostics companies that could develop similar rapid molecular solutions.

Competitive Landscape

Competes against traditional send-out PCR services (e.g., Eurofins) and existing lab-based kit providers (e.g., Lonza's MycoAlert, Minerva Biolabs). Certus differentiates by claiming a superior combination of speed (30 min), simplicity (5 min hands-on), and laboratory-quality reliability for on-site use, targeting the gap between unreliable rapid tests and slow but accurate PCR.